(MEDP) Medpace Holdings - Overview

Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 14.144m USD | Total Return: 75.3% in 12m

Clinical Trials, Drug Development, Medical Devices, Research Services
Total Rating 63
Safety 57
Buy Signal 0.85
Diagnostics & Research
Industry Rotation: +13.4
Market Cap: 14.1B
Avg Turnover: 144M USD
ATR: 3.72%
Peers RS (IBD): 88.3
Risk 5d forecast
Volatility43.0%
Rel. Tail Risk-12.4%
Reward TTM
Sharpe Ratio1.07
Alpha42.18
Character TTM
Beta1.040
Beta Downside0.963
Drawdowns 3y
Max DD39.38%
CAGR/Max DD0.99
EPS (Earnings per Share) EPS (Earnings per Share) of MEDP over the last years for every Quarter: "2021-03": 1.14, "2021-06": 1.06, "2021-09": 1.29, "2021-12": 1.32, "2022-03": 1.69, "2022-06": 1.46, "2022-09": 2.05, "2022-12": 2.12, "2023-03": 2.27, "2023-06": 1.93, "2023-09": 2.22, "2023-12": 2.46, "2024-03": 3.2, "2024-06": 2.75, "2024-09": 3.01, "2024-12": 3.6813, "2025-03": 3.67, "2025-06": 3.103, "2025-09": 3.86, "2025-12": 4.67, "2026-03": 0,
EPS CAGR: -39.55%
EPS Trend: 11.4%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of MEDP over the last years for every Quarter: 2021-03: 259.965, 2021-06: 278.293, 2021-09: 295.567, 2021-12: 308.552, 2022-03: 330.947, 2022-06: 351.207, 2022-09: 383.744, 2022-12: 394.098, 2023-03: 434.074, 2023-06: 460.868, 2023-09: 492.499, 2023-12: 498.401, 2024-03: 511.044, 2024-06: 528.104, 2024-09: 533.317, 2024-12: 536.589, 2025-03: 558.57, 2025-06: 603.311, 2025-09: 659.903, 2025-12: 708.45, 2026-03: null,
Rev. CAGR: 22.50%
Rev. Trend: 97.8%
Last SUE: 0.78
Qual. Beats: 0

Warnings

Altman Z'' -0.48 < 1.0 - financial distress zone

Tailwinds

No distinct edge detected

Description: MEDP Medpace Holdings

Medpace Holdings, Inc. (MEDP) is a contract research organization (CRO) providing drug and medical device development services globally. CROs support pharmaceutical, biotechnology, and medical device companies by outsourcing clinical trial activities.

The company offers a comprehensive range of services across all phases of clinical development (I-IV). This includes study design, central laboratory services, project management, regulatory affairs, clinical monitoring, data management, and pharmacovigilance. This full-service model is common in the CRO industry, allowing clients to streamline their research and development processes.

Additional services include bio-analytical laboratory testing, clinical human pharmacology, imaging services, and electrocardiography reading support. These specialized offerings enhance the companys capabilities in supporting complex clinical trials.

To gain further insights into MEDPs financial performance and market position, consider exploring its detailed financials on ValueRay.

Headlines to Watch Out For
  • Biotechnology R&D spending directly impacts Medpace revenue
  • Regulatory changes in drug approval processes create uncertainty
  • Competition from other CROs pressures Medpace pricing
  • Biotech funding environment influences new study initiations
  • Labor costs for scientific personnel affect profitability
Piotroski VR‑10 (Strict) 8.0
Net Income: 451.1m TTM > 0 and > 6% of Revenue
FCF/TA: 0.36 > 0.02 and ΔFCF/TA 8.63 > 1.0
NWC/Revenue: -14.00% < 20% (prev -3.57%; Δ -10.42% < -1%)
CFO/TA 0.36 > 3% & CFO 713.2m > Net Income 451.1m
Net Debt (-246.6m) to EBITDA (551.9m): -0.45 < 3
Current Ratio: 0.74 > 1.5 & < 3
Outstanding Shares: last quarter (29.0m) vs 12m ago -9.53% < -2%
Gross Margin: 30.06% > 18% (prev 0.31%; Δ 2.97k% > 0.5%)
Asset Turnover: 124.1% > 50% (prev 100.4%; Δ 23.75% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -0.48
A: -0.18 (Total Current Assets 989.6m - Total Current Liabilities 1.34b) / Total Assets 1.98b
B: -0.23 (Retained Earnings -460.0m / Total Assets 1.98b)
C: 0.26 (EBIT TTM 537.7m / Avg Total Assets 2.04b)
D: -0.31 (Book Value of Equity -464.6m / Total Liabilities 1.52b)
Altman-Z'' Score: -0.48 = B
Beneish M -2.91
DSRI: 1.13 (Receivables 402.1m/296.4m, Revenue 2.53b/2.11b)
GMI: 1.04 (GM 30.06% / 31.12%)
AQI: 0.96 (AQ_t 0.37 / AQ_t-1 0.39)
SGI: 1.20 (Revenue 2.53b / 2.11b)
TATA: -0.13 (NI 451.1m - CFO 713.2m) / TA 1.98b)
Beneish M-Score: -2.91 (Cap -4..+1) = A
What is the price of MEDP shares? As of April 08, 2026, the stock is trading at USD 508.52 with a total of 329,411 shares traded.
Over the past week, the price has changed by +5.90%, over one month by +6.26%, over three months by -17.06% and over the past year by +75.29%.
Is MEDP a buy, sell or hold? Medpace Holdings has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold MEDP.
  • StrongBuy: 2
  • Buy: 0
  • Hold: 10
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the MEDP price?
Analysts Target Price 500.1 -1.7%
Medpace Holdings (MEDP) - Fundamental Data Overview as of 06 April 2026
P/E Trailing = 32.6566
P/E Forward = 29.1545
P/S = 5.5898
P/B = 30.8214
P/EG = 3.0109
Revenue TTM = 2.53b USD
EBIT TTM = 537.7m USD
EBITDA TTM = 551.9m USD
Long Term Debt = 113.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 23.2m USD (from shortTermDebt, last quarter)
Debt = 250.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -246.6m USD (from netDebt column, last quarter)
Enterprise Value = 13.90b USD (14.14b + Debt 250.5m - CCE 497.0m)
 Interest Coverage Ratio = unknown (Ebit TTM 537.7m / Interest Expense TTM 0.0)
 EV/FCF = 19.61x (Enterprise Value 13.90b / FCF TTM 708.7m)
FCF Yield = 5.10% (FCF TTM 708.7m / Enterprise Value 13.90b)
FCF Margin = 28.01% (FCF TTM 708.7m / Revenue TTM 2.53b)
Net Margin = 17.83% (Net Income TTM 451.1m / Revenue TTM 2.53b)
Gross Margin = 30.06% ((Revenue TTM 2.53b - Cost of Revenue TTM 1.77b) / Revenue TTM)
Gross Margin QoQ = 28.98% (prev 29.84%)
Tobins Q-Ratio = 7.03 (Enterprise Value 13.90b / Total Assets 1.98b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 250.5m)
Taxrate = 13.84% (21.7m / 156.8m)
NOPAT = 463.3m (EBIT 537.7m * (1 - 13.84%))
Current Ratio = 0.74 (Total Current Assets 989.6m / Total Current Liabilities 1.34b)
Debt / Equity = 0.55 (Debt 250.5m / totalStockholderEquity, last quarter 459.1m)
Debt / EBITDA = -0.45 (Net Debt -246.6m / EBITDA 551.9m)
Debt / FCF = -0.35 (Net Debt -246.6m / FCF TTM 708.7m)
Total Stockholder Equity = 379.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 22.13% (Net Income 451.1m / Total Assets 1.98b)
RoE = 118.8% (Net Income TTM 451.1m / Total Stockholder Equity 379.7m)
RoCE = 109.0% (EBIT 537.7m / Capital Employed (Equity 379.7m + L.T.Debt 113.6m))
RoIC = 122.0% (NOPAT 463.3m / Invested Capital 379.7m)
WACC = 9.47% (E(14.14b)/V(14.39b) * Re(9.64%) + D(250.5m)/V(14.39b) * Rd(0.0%) * (1-Tc(0.14)))
Discount Rate = 9.64% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -4.60%
[DCF] Terminal Value 76.94% ; FCFF base≈654.1m ; Y1≈806.9m ; Y5≈1.38b
[DCF] Fair Price = 646.9 (EV 18.11b - Net Debt -246.6m = Equity 18.36b / Shares 28.4m; r=9.47% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 11.40 | EPS CAGR: -39.55% | SUE: -4.0 | # QB: 0
Revenue Correlation: 97.80 | Revenue CAGR: 22.50% | SUE: 0.78 | # QB: 0
EPS next Quarter (2026-06-30): EPS=4.10 | Chg7d=+0.003 | Chg30d=+0.004 | Revisions Net=+1 | Analysts=7
EPS current Year (2026-12-31): EPS=17.39 | Chg7d=+0.013 | Chg30d=-0.005 | Revisions Net=+8 | Growth EPS=+13.8% | Growth Revenue=+11.0%
EPS next Year (2027-12-31): EPS=19.21 | Chg7d=+0.038 | Chg30d=+0.017 | Revisions Net=+7 | Growth EPS=+10.5% | Growth Revenue=+7.7%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.6% (Discount Rate 9.6% - Earnings Yield 3.1%)
[Growth] Growth Spread = +9.8% (Analyst 16.4% - Implied 6.6%)
External Resources
Dataroma Stockcircle